From what I understand, BOS suspension is purely related to the change in activities.
However, the valuation of BOS of about 5 million dollars in the RGM transaction would probably be based upon BOS sale of it's intellectual property to CBI. CBI in turn, probably can't pay for BOS technology without GL Biochem taking them over.
That's my take anyway. So if you read an announcement in the near future that says CBI (CBTE) and GL Biochem have completed their merger, then all is good.
BOS Price at posting:
2.3¢ Sentiment: Hold Disclosure: Held
